Skip to main content

Table 1 Characteristics of HIV-infected children on ART in the Maggsen Cohort Study.a–b Dakar, Senegal

From: Low prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study

Characteristics

2–5 y

5–10 y

10–18 y

Total

P value

(N = 18)

(N = 83)

(N = 153)

(N = 254)

 

Study site

        

0.79

 Albert Royer Hospital

13

(72)

61

(73)

106

(69)

180

(71)

 

 Roi Baudouin Hospital

5

(28)

22

(27)

47

(31)

74

(29)

 

Girls

6

(33)

37

(45)

68

(44)

111

(44)

0.65

WHO classificationc

        

0.03

 Stage 1–2

8

(44)

14

(17)

29

(19)

51

(20)

 

 Stage 3–4

10

(56)

69

(83)

124

(81)

203

(80)

 

Moderate wastingd

0

14

(17)

49

(32)

63

(25)

0.002

WHZ/BMIZ, median (IQR)

−0.7

(−1.6–0.2)

−1.1

(−1.8 – −0.4)

−1.6

(−2.2 – − 0.9)

−1.4

(−2.0 – − 0.7)

< 0.0001

HAZ, median (IQR)

− 1.3

(−2.0 – − 1.0)

−1.1

(− 1.7 – − 0.3)

−1.2

(− 1.9 – − 0.5)

−1.2

(− 1.8 – − 0.5)

0.37

Puberty onset

0

0

92

(60)

92

(36)

< 0.0001

CD4 < 500 cells/mm3

2

(11)

7

(9)

38

(25)

47

(19)

0.01

Viral load < 40 copies/mL

7

(39)

57

(70)

108

(71)

172

(68)

0.02

Time on ART in month, median (IQR)

22

(11–30)

47

(31–61)

64

(34–100)

54

(32–84)

< 0.0001

ARV drug classes

 2NRTI/NNRTI

15

(83)

65

(78)

72

(47)

152

(60)

 

 2NRTI/PI

3

(17)

15

(18)

28

(18)

46

(18)

 

 NRTI/NNRTI/nRTI

0

1

(1)

30

(20)

31

(12)

 

 NRTI/nRTI/PI

0

2

(3)

22

(14)

24

(10)

 

 NRTI/nRTI/PI/II

0

0

1

(1)

1

(0)

 
  1. aAbbreviations: ART antiretroviral treatment, BMIZ body mass index for age z-score, HAZ height for age z-score, II integrase inhibitor, nRTI nucleotide reverse-transcriptase inhibitor, NRTI nucleoside reverse-transcriptase inhibitor, NNRTI non-nucleoside reverse-transcriptase inhibitor, IQR interquartile range, PI/r protease inhibitor boosted, RTV ritonavir, WHZ weight for height z-score
  2. bData are N (%) unless otherwise indicated
  3. cWHO symptoms classification: highest stage reached by the child before ART initiation
  4. dModerate wasting (moderate acute malnutrition) is defined for both weight-for-height z scores (WHZ) in children < 5 years or body mass index-for-age z score (BMIZ) in children ≥5 years as being ≥ − 3 and < −2 [20, 21]